Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Urigen Pharmaceuticals and Hyaluron Contract Manufacturing have established a partnership to develop URG101, Urigen's proprietary fixed dose combination of FDA-approved drugs targeting painful bladder syndrome.
Subscribe to our email newsletter
William Garner, president and CEO of Urigen, said: “Urigen’s development program with Hyaluron is a critical step forward for URG101. We look forward to working with the drug development team at Hyaluron to provide a solution to painful bladder syndrome through the commercialization of our product.”